North America Liver Cancer Diagnostics Market SWOT Analysis, Size, Share, Trends, Growth and Forecast from 2022 to 2028

 

The liver cancer diagnostics market in North America is expected to grow from US$ 3,843.93 million in 2021 to US$ 6,666.24 million by 2028. It is estimated to grow at a CAGR of 8.2% from 2021 to 2028.

 North America Liver Cancer Diagnostics Market The ability to accurately diagnose liver cancer progression is critical for selecting the appropriate treatment option. Further, various companies and organizations have taken enormous initiatives to develop and implement innovative solutions for the early identification of this disease in response to the rising demand. For instance, in March 2020, Roche Holding AG's Elecsys GALAD score received the US Food and Drug Administration's breakthrough device status for the early detection of an advanced form of liver cancer. North America Liver Cancer Diagnostics Market The Swiss drugmaker's calculator combines factors including age, gender, and biomarker results to detect early-stage hepatocellular carcinoma, which is the most common form of liver cancer. Further, Elecsys GALAD score is designed to support clinicians by providing them with a timely and accurate diagnosis of hepatocellular carcinoma.

North America Liver Cancer Diagnostics Market

North America Liver Cancer Diagnostics Market Liver cancer, particularly hepatocellular carcinoma (HCC), is one of the leading causes of cancer-related mortality worldwide. The increasing prevalence of liver disease, particularly due to rising rates of chronic hepatitis B and C infections, alcohol-related liver disease, and non-alcoholic fatty liver disease (NAFLD), has led to an increase in the number of liver cancer cases. In North America, the growing demand for effective and early diagnostic tools to detect liver cancer has fostered the expansion of the liver cancer diagnostics market.This article will examine the factors driving the growth of the North American liver cancer diagnostics market, key diagnostic methods, market challenges, and future prospects in the region.

📚 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐂𝐨𝐩𝐲@ https://www.businessmarketinsights.com/sample/BMIRE00025043

North America Liver Cancer Diagnostics Market The research and development (R&D) expenditure in 2021 was US$ 14.65 billion, and in 2020, it was US$ 13.17 billion. The research and development (R&D) expenditure grew by 14% on a core basis in F. Hoffmann-La Roche Ltd., North America Liver Cancer Diagnostics Market mostly driven by late-stage investments in oncology, ophthalmology, and personalized healthcare. In 2021, the R&D investment in the diagnostic division was US$ 1,878.92 million. Similarly, In November 2019, EXACT Sciences Corporation received the Food and Drug Administration's (FDA) breakthrough designation for its blood-based test for early detection of liver cancer.Additionally, in June 2020, National Institutes of Health (NIH) scientists developed blood tests to help improve liver cancer screening, led by researchers at the National Cancer Institute (NCI). In addition, in June 2019, CancerSEEK, a liquid biopsy test, was designed by researchers at Johns Hopkins University. North America Liver Cancer Diagnostics Market The test was designed to diagnose multiple cancers, including stomach, liver, ovarian, and esophageal, at an early stage, facilitating early treatment. Therefore, the increasing R&D investments and development of diagnostic tests for the detection of liver cancer are driving the liver cancer diagnostics market.

With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America Liver cancer diagnostics market at a substantial CAGR during the forecast period.

𝐓𝐡𝐞 𝐋𝐢𝐬𝐭 𝐨𝐟 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬

Abbott

bioMerieux SA

F. HOFFMANN-LA ROCHE LTD.

Illumina, Inc.

Koninklijke Philips N.V.

QIAGEN

Siemens Healthineers AG

THERMO FISHER SCIENTIFIC INC.

GE Healthcare

Perspectum

📚𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭 𝐋𝐢𝐧𝐤 @ https://www.businessmarketinsights.com/reports/north-america-liver-cancer-diagnostics-market

Drivers of Market Growth

Several factors are contributing to the expansion of the liver cancer diagnostics market in North America:

1.Rising Incidence of Liver Cancer: North America Liver Cancer Diagnostics Market The number of liver cancer cases in North America has been steadily increasing, driven by the growing incidence of risk factors like chronic hepatitis infections, alcohol abuse, and NAFLD. The Centers for Disease Control and Prevention (CDC) has reported a significant rise in the rates of liver cancer in the United States in recent years, underscoring the urgent need for improved diagnostic tools.

2.Technological Advancements in Diagnostic Tools: North America Liver Cancer Diagnostics Market The development of advanced imaging technologies such as contrast-enhanced ultrasound (CEUS), elastography, and molecular diagnostic tests has made early detection of liver cancer more accurate and accessible. The increasing adoption of non-invasive diagnostic technologies such as liquid biopsy and blood-based biomarker assays has also contributed to the market’s growth.

3.Government Initiatives and Awareness Campaigns: North America Liver Cancer Diagnostics Market Governments and health organizations are investing in liver cancer awareness and screening programs, aiming to detect liver cancer in its early stages when treatment options are more effective. This has spurred the demand for liver cancer diagnostic services, driving market growth.

4.Improved Healthcare Infrastructure: North America Liver Cancer Diagnostics Market The availability of state-of-the-art healthcare facilities, especially in urban areas across the United States and Canada, has increased the accessibility of diagnostic tests. The growing number of specialized cancer centers is contributing to the rise in diagnostic procedures.

5.Aging Population: North America Liver Cancer Diagnostics Market North America has an aging population, and with age being one of the major risk factors for liver cancer, the incidence of liver cancer is expected to rise. This demographic trend is expected to drive the demand for liver cancer diagnostic services, as older individuals are more likely to develop liver disease and cancer.

Market Overview

Liver cancer diagnostics include various methods to detect, stage, and evaluate liver cancer. These diagnostic tests are critical in providing timely and accurate diagnosis, which is essential for deciding the appropriate treatment options. The market for liver cancer diagnostics in North America is expected to experience robust growth due to advancements in diagnostic technologies, increased awareness of liver cancer, and the high burden of liver-related diseases in the region.

The diagnostic methods used for liver cancer include imaging techniques, biomarker tests, and liver biopsy. Imaging techniques such as ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) are widely used for liver cancer detection. Biomarker tests, including serum biomarkers like alpha-fetoprotein (AFP), are also important in diagnosing liver cancer. In some cases, a biopsy may be performed to confirm the diagnosis and determine the cancer’s stage.

Key Diagnostic Methods

Several diagnostic tools are used to diagnose liver cancer, and the market for these methods is expected to grow with advancements in technology and increased healthcare investment. Key diagnostic methods include:

1. Imaging Techniques

  • Ultrasound: Ultrasound is often the first imaging technique used to detect liver cancer. It is non-invasive, inexpensive, and widely available, making it an essential tool in the diagnostic process.
  • CT Scan: A computed tomography (CT) scan is more detailed than ultrasound and can help identify liver tumors and assess their size and location. It is often used in conjunction with other tests for accurate diagnosis and staging.
  • MRI: Magnetic resonance imaging (MRI) is more precise than CT for detecting liver cancer. It is particularly useful in identifying smaller tumors and assessing the liver's functional characteristics. MRI is also used to monitor the progress of cancer treatments.

2. Biomarkers and Blood Tests

  • Alpha-fetoprotein (AFP): AFP is a protein often elevated in liver cancer patients. A blood test to measure AFP levels can provide important information for diagnosing liver cancer, though it is not always reliable as a sole diagnostic marker.
  • Other Biomarkers: In addition to AFP, several other biomarkers, such as des-gamma-carboxy prothrombin (DCP) and glypican-3, have shown promise in diagnosing liver cancer. These biomarkers can be used in combination to increase diagnostic accuracy.

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications.

You can see this-

North America Liquid Biopsy Market- https://postyourarticle.com/north-america-liquid-biopsy-market-identifying-roles-and-objectives-in-coming-years-till-2027/

North America Healthcare Contract Research Organizations (CRO) Services Market-  https://www.globalpostnews.com/uncategorized/north-america-healthcare-contract-research-organizations-cro-services-market-size-growth-status-analysis-and-forecast-2027/

North America Railway Cyber Security Market- https://www.openpr.com/news/3929498/north-america-coffee-beans-market-regional-share-global-size

North America Acetonitrile Market- https://businessmarketreportsblog.wordpress.com/2025/03/21/north-america-acetonitrile-market-size-growth-status-analysis-and-forecast-2027/


Comments

Popular posts from this blog

Europe Electric Ship Market Key Players, Growth, Trends, Share, Opportunities, Forecast 2028

Europe Electric Ship Market Key Players, Growth, Trends, Share, Opportunities, Forecast 2028

Europe Electric Ship Market Key Details and Outlook by Top Companies till 2028